Experienced in Atypical Teratoid Rhabdoid Tumor (ATRT)

Aru Narendran

Calgary, AB, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Atypical Teratoid Rhabdoid Tumor (ATRT)
Calgary, AB, CA 
OverviewLocationsClinical Research

Overview

Aru Narendran practices in Calgary, Canada. Narendran is rated as an Experienced expert by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). Their top areas of expertise are Neurocutaneous Melanosis, Embryonal Tumor with Multilayered Rosettes, Rhabdoid Tumor, Neuroblastoma, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 81 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Atypical Teratoid Rhabdoid Tumor (ATRT).

Locations

Calgary, AB, Canada
Other Locations
Calgary, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children with Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)
A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children with Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)
Enrollment Status: Recruiting
Publish Date: December 10, 2024
Intervention Type: Drug, Radiation
Study Drugs: Alemtuzumab, Sirolimus
Study Phase: Phase 2
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Carfilzomib, Cyclophosphamide, Etoposide
Study Phase: Phase 1
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trial

81 Total Publications

PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.
PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.
Journal: Human vaccines & immunotherapeutics
Published: October 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Narendran's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 21 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile